A Review of Emerging ARNI Data in HFrEF
Published: 27 November 2019
6m 8sPart 1 ARIADNE in Review Uwe Zeymer
3m 33sPart 2 Commentary on ARIADNE Andrew JS Coats, Scott Solomon
6m 57sPart 3 PROVE-HF in Review James L Januzzi
8m 25sPart 4 EVALUATE in Review Akshay S Desai
6m 20sPart 5 Commentary on PROVE-HF and EVALUATE Scott Solomon, Andrew JS Coats
6m 30sPart 6 TRANSITION-CHF in Review Rolf Wachter
Despite advances in cardiovascular therapy, heart failure (HF) continues to be a leading cause of morbidity and mortality with significant cost to the health care system. Evidence for the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan has demonstrated significant reductions in all-cause mortality, cardiovascular mortality, and HF hospitalization compared with enalapril and international guidelines currently recommend its use.
Despite this evidence and the recommendation of clinical guidelines, ARNI therapy is not initiated in the majority of eligible patients. Evidence suggests a lack of understanding of a patient’s risk and also the benefit of life saving therapies by physicians is a primary cause of under-utilization.
Increased education is needed so clinicians fully understand the patient’s risk, as well as latest mechanistic and clinical data to ensure confidence in using newer therapies.
This educational program summarises new data covering ARNI therapy for heart failure with reduced ejection fraction (HFrEF) presented at the European Society of Cardiology (ESC) 2019 congress.
- Review updated data of ARNI therapy for HFrEF present at the ESC 2019
- Understand the current utilisation of ARNI therapy in HFrEF (guidelines and databases)
- Interpret potential mechanistic data related to the clinical benefit of ARNI therapy including imaging and biomarker data
- Apply new data covering the utilization of ARNI therapy in complex patients including recently decompensated and hospitalized patients.
More from this programme
ARIADNE in Review
Commentary on ARIADNE
PROVE-HF in Review
EVALUATE in Review
Commentary on PROVE-HF and EVALUATE
TRANSITION-CHF in Review
PIONEER in Review
Prof David A Morrow the Director of the Samuel A. Levine Cardiac Intensive Care Unit in the Division of Cardiovascular Medicine at Brigham and Women's Hospital and a Professor of Medicine at Harvard Medical School. He directs the TIMI Biomarker Program